Malcolm Brenner, MD, PhD

Full Affiliate Member, Research Institute
Houston Methodist


Dr. Brenner completed his postdoctoral training in 1981 and joined the Clinical Research Centre of Northwick Park Hospital in London, England as a MRC Clinical Scientist and Honorary Senior Registrar. He also began lecturing in Haematology at the Royal Free Hospital and Hospital for Sick Children, also in London.

Dr. Brenner joined the faculty at the University of Tennessee in Memphis as a Professor in the Departments of Pediatrics and Medicine in 1990. He also became the Director of the Bone Marrow Transplant Division of the St. Jude Children's Research Hospital that same year. He later directed the Cell and Gene Therapy Program at St. Jude's from 1994 until 1997, when he assumed his current positions at the Baylor College of Medicine.

Description of Research

Dr. Brenner's research focuses on gene transfer to stem cells and to effector cells of the immune system. His research group was one of the first to use gene transfer in human subjects, establishing the feasibility of tracking human stem cells and their progeny in subjects with cancer. Dr. Brenner also develops tumor vaccines for pediatric and hematological malignancies, using genetic modification with retroviral and adenoviral vectors.

Areas Of Expertise

Cell therapy Gene therapy Stem cells Vectors
Education & Training

PhD , Cambridge University

Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer
Rosewell Shaw, A, Porter, CE, Watanabe, N, Tanoue, K, Sikora, A, Gottschalk, S, Brenner, MK & Suzuki, M 2017, Molecular Therapy, vol 25, no. 11, pp. 2440-2451. DOI: 10.1016/j.ymthe.2017.09.010

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Ramos, CA, Ballard, B, Zhang, H, Dakhova, O, Gee, AP, Mei, Z, Bilgi, M, Wu, MF, Liu, H, Grilley, B, Bollard, CM, Chang, BH, Rooney, CM, Brenner, MK, Heslop, HE, Dotti, G & Savoldo, B 2017, Journal of Clinical Investigation, vol 127, no. 9, pp. 3462-3471. DOI: 10.1172/JCI94306

Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of Chimeric antigen receptor t cells in solid tumors
Tanoue, K, Shaw, AR, Watanabe, N, Porter, C, Rana, B, Gottschalk, S, Brenner, M & Suzuki, M 2017, Cancer Research, vol 77, no. 8, pp. 2040-2051. DOI: 10.1158/0008-5472.CAN-16-1577

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
Heczey, A, Louis, CU, Savoldo, B, Dakhova, O, Durett, A, Grilley, B, Liu, H, Wu, MF, Mei, Z, Gee, A, Mehta, B, Zhang, H, Mahmood, N, Tashiro, H, Heslop, HE, Dotti, G, Rooney, CM & Brenner, MK 2017, Molecular Therapy. DOI: 10.1016/j.ymthe.2017.05.012

Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
Mohammed, S, Sukumaran, S, Bajgain, P, Watanabe, N, Heslop, HE, Rooney, CM, Brenner, MK, Fisher, WE, Leen, AM & Vera, JF 2017, Molecular Therapy, vol 25, no. 1, pp. 249-258. DOI: 10.1016/j.ymthe.2016.10.016

Next Steps in the CAR Journey of a Thousand Miles
Brenner, MK 2017, Molecular Therapy. DOI: 10.1016/j.ymthe.2017.09.013

Fine-tuning the CAR spacer improves T-cell potency
Watanabe, N, Bajgain, P, Sukumaran, S, Ansari, S, Heslop, HE, Rooney, CM, Brenner, MK, Leen, AM & Vera, JF 2016, OncoImmunology, vol 5, no. 12, e1253656. DOI: 10.1080/2162402X.2016.1253656

Improving the safety of T-Cell therapies using an inducible caspase-9 gene
Zhou, X & Brenner, MK 2016, Experimental Hematology, vol 44, no. 11, pp. 1013-1019. DOI: 10.1016/j.exphem.2016.07.011

Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape
Hegde, M, Mukherjee, M, Grada, Z, Pignata, A, Landi, D, Navai, SA, Wakefield, A, Fousek, K, Bielamowicz, K, Chow, KKH, Brawley, VS, Byrd, TT, Krebs, S, Gottschalk, S, Wels, WS, Baker, ML, Dotti, G, Mamonkin, M, Brenner, MK, Orange, JS & Ahmed, N 2016, Journal of Clinical Investigation, vol 126, no. 8, pp. 3036-3052. DOI: 10.1172/JCI83416

Clinical responses with T lymphocytes targeting malignancy-associated ? light chains
Ramos, CA, Savoldo, B, Torrano, V, Ballard, B, Zhang, H, Dakhova, O, Liu, E, Carrum, G, Kamble, RT, Gee, AP, Mei, Z, Wu, MF, Liu, H, Grilley, B, Rooney, CM, Brenner, MK, Heslop, H & Dotti, G 2016, Journal of Clinical Investigation, vol 126, no. 7, pp. 2588-2596. DOI: 10.1172/JCI86000

3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirus
Del Bufalo, F, Manzo, T, Hoyos, V, Yagyu, S, Caruana, I, Jacot, J, Benavides, O, Rosen, D & Brenner, MK 2016, Biomaterials, vol 84, pp. 76-85. DOI: 10.1016/j.biomaterials.2016.01.030

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
Gargett, T, Yu, W, Dotti, G, Yvon, ES, Christo, SN, Hayball, JD, Lewis, ID, Brenner, MK & Brown, MP 2016, Molecular Therapy. DOI: 10.1038/mt.2016.63

CAR-T cell therapy for lymphoma
Ramos, CA, Heslop, HE & Brenner, MK 2016, Annual Review of Medicine, vol 67, pp. 165-183. DOI: 10.1146/annurev-med-051914-021702

Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch
Chang, EC, Liu, H, West, JA, Zhou, X, Dakhova, O, Wheeler, DA, Heslop, HE, Brenner, MK & Dotti, G 2015, Molecular Therapy. DOI: 10.1038/mt.2015.217

A safeguard system for induced pluripotent stem cell-derived rejuvenated T cell therapy
Ando, M, Nishimura, T, Yamazaki, S, Yamaguchi, T, Kawana-Tachikawa, A, Hayama, T, Nakauchi, Y, Ando, J, Ota, Y, Takahashi, S, Nishimura, K, Ohtaka, M, Nakanishi, M, Miles, JJ, Burrows, SR, Brenner, MK & Nakauchi, H 2015, Stem Cell Reports, vol 5, no. 4, pp. 597-608. DOI: 10.1016/j.stemcr.2015.07.011

Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers
Hoyos, V, Del Bufalo, F, Yagyu, S, Ando, M, Dotti, G, Suzuki, M, Bouchier-Hayes, L, Alemany, R & Brenner, MK 2015, Molecular Therapy, vol 23, no. 9, pp. 1497-1506. DOI: 10.1038/mt.2015.110

An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells
Yagyu, S, Hoyos, V, Del Bufalo, F & Brenner, MK 2015, Molecular Therapy, vol 23, no. 9, pp. 1475-1485. DOI: 10.1038/mt.2015.100

A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies
Mamonkin, M, Rouce, RH, Tashiro, H & Brenner, MK 2015, Blood, vol 126, no. 8, pp. 983-992. DOI: 10.1182/blood-2015-02-629527

Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies
Naik, S, Martinez, C, Leung, K, Sasa, G, Nguyen, NY, Wu, MF, Gottschalk, S, Brenner, M, Heslop, H & Krance, R 2015, Biology of Blood and Marrow Transplantation, vol 21, no. 7, pp. 1266-1272. DOI: 10.1016/j.bbmt.2015.02.024

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation
Zhou, X, Dotti, G, Krance, RA, Martinez, CA, Naik, S, Kamble, RT, Durett, AG, Dakhova, O, Savoldo, B, Stasi, AD, Spencer, DM, Lin, YF, Liu, H, Grilley, BJ, Gee, AP, Rooney, CM, Heslop, HE & Brenner, MK 2015, Blood, vol 125, no. 26, pp. 4103-4113. DOI: 10.1182/blood-2015-02-628354